Emory University (US) finds little difference between percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass graft (CABG)
This article was originally published in Clinica
Emory University (US) researchers say there is little difference in either cost or quality of life between angioplasty and bypass patients after three years. Angioplasty's initial cost-advantage "is largely, although probably not completely lost," says William Weintraub, writing in Circulation (November).
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.